Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kyverna Therapeutics Inc (KYTX)

Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kyverna Therapeutics Inc 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 USA

https://kyvernatx.com Employees: 112 P: 510-626-8331

Sector:

Medical

Description:

Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif.

Key Statistics

Overview:

Market Capitalization, $K 358,251
Enterprise Value, $K 261,631
Shares Outstanding, K 43,796
Annual Sales, $ 0 K
Annual Net Income, $ -127,480 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -36,790 K
EBIT, $ -171,590 K
EBITDA, $ -169,460 K
60-Month Beta 3.66
% of Insider Shareholders 22.00%
% of Institutional Shareholders 18.08%
Float, K 34,161
% Float 78.00%
Short Volume Ratio 0.39

Growth:

1-Year Return 78.25%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.85 on 11/12/25
Next Earnings Date 03/26/26
Earnings Per Share ttm -3.73
EPS Growth vs. Prev Qtr 12.37%
EPS Growth vs. Prev Year -6.25%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

KYTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -77.94%
Return-on-Assets % -65.83%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.25
Book Value/Share 3.51
Interest Coverage -909.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar